Search
Kestra Medical Technologies Ltd
KMTSAdd to Watchlist
19.930USD
+0.850+4.45%
Close 06/18, 16:00（ET）Quotes delayed by 15 min
1.16BMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-06-18The current earnings forecast score of Kestra Medical Technologies Ltd is 8.86, ranking 10 out of 203 in the Healthcare Equipment & Supplies industry. The average price target is 28.00, with a high of 32.00 and a low of 22.00.
Analyst Rating
Based on
7
analysts
Buy
Current Rating
27.400
Target Price
+37.48%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
94
Total
3
Median
7
Average
Company name
Ratings
Analysts
Kestra Medical Technologies Ltd
KMTS
7
Boston Scientific Corp
BSX
37
Intuitive Surgical Inc
ISRG
35
Edwards Lifesciences Corp
EW
34
Veeva Systems Inc
VEEV
30
Thermo Fisher Scientific Inc
TMO
30
1
2
3
...
19
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
FAQs
What is Kestra Medical Technologies Ltd's expected revenue for the next quarter?
Kestra Medical Technologies Ltd's expected revenue is 26.48M.
What is Kestra Medical Technologies Ltd's price target?
Analysts forecast that Kestra Medical Technologies Ltd's price target is USD 28.00, with the highest forecast at USD 32.00 and the lowest forecast at USD 22.00.
How have Kestra Medical Technologies LtdKMTS's recent earnings per share performed?
The market expectation was USD -0.61, while Kestra Medical Technologies LtdKMTS's earnings per share (EPS) for the previous quarter was USD -0.64. EPS for the next quarter is expected at USD -0.60.
What is the analyst rating for Kestra Medical Technologies Ltd?
Based on the ratings of Kestra Medical Technologies Ltd's stock from 7 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.
